A preclinical study by Poon et al. used the non-opioid analgesic drug nefopam (benzoxazocine class), and reported a decrease in ß-catenin levels and cellular proliferation rate, as well as a reduction in tumor number and volume in Apc+/Apc1638N mice (Table 1) (60). Here, APC is linked to neoplasm.